PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...
Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, until January 2028, to comply with the change. Red 3, also known as ...
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improving track record of beating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback